Degenerative Mitral Valve Disease
0
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Polares MedicalCA - Palo Alto
2 programsTranscatheter mitral valve repairN/A1 trial
Transcatheter mitral valve repairN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Polares MedicalTranscatheter mitral valve repair
Polares MedicalTranscatheter mitral valve repair
Edwards LifesciencesEdwards PASCAL System
Clinical Trials (3)
Total enrollment: 1,258 patients across 3 trials
Early Feasibility Study of the PLAR Implant and Delivery System to Treat Degenerative Mitral Regurgitation
Start: Apr 2021Est. completion: Dec 20221 patients
N/ATerminated
EXPLORE DMR: Early Feasibility Study of the PLAR Implant and Delivery System to Treat Degenerative Mitral Regurgitation
Start: Mar 2021Est. completion: Dec 202610 patients
N/ANot Yet Recruiting
Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
Start: Nov 2018Est. completion: Jun 20311,247 patients
N/AActive Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.